

0590  
0574

# 10



ENTERED

OIPE

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/024,535A

DATE: 05/17/2002

TIME: 14:13:47

Input Set : A:\SEQ.10-024535.txt

Output Set: N:\CRF3\05172002\J024535A.raw

3 <110> APPLICANT: MARCEL et al.  
 5 <120> TITLE OF INVENTION: Therapeutic methods and compositions for the treatment  
 6 of impaired interpersonal and behavioral disorders  
 8 <130> FILE REFERENCE: P07479US01/BAS  
 10 <140> CURRENT APPLICATION NUMBER: US 10/024,535A  
 11 <141> CURRENT FILING DATE: 2001-12-21  
 13 <150> PRIOR APPLICATION NUMBER: PCT/EP00/06259  
 14 <151> PRIOR FILING DATE: 2000-06-22  
 16 <150> PRIOR APPLICATION NUMBER: US/140,563  
 17 <151> PRIOR FILING DATE: 1999-06-23  
 19 <160> NUMBER OF SEQ ID NOS: 10  
 21 <170> SOFTWARE: PatentIn Ver. 2.1  
 23 <210> SEQ ID NO: 1  
 24 <211> LENGTH: 5  
 25 <212> TYPE: PRT  
 26 <213> ORGANISM: Artificial Sequence  
 28 <220> FEATURE:  
 29 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve  
 therapeutic  
 30 effects in mammals.  
 32 <220> FEATURE:  
 33 <221> NAME/KEY: MISC\_FEATURE  
 34 <222> LOCATION: (1)..(1)  
 35 <223> OTHER INFORMATION: Xaa is Glp  
 38 <400> SEQUENCE: 1  
 W--> 39 Xaa His Asn Pro Arg  
 40 1 5  
 43 <210> SEQ ID NO: 2  
 44 <211> LENGTH: 5  
 45 <212> TYPE: PRT  
 46 <213> ORGANISM: Artificial Sequence  
 48 <220> FEATURE:  
 49 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve  
 therapeutic  
 50 effects in mammals.  
 52 <400> SEQUENCE: 2  
 53 Gln His Asn Pro Arg  
 54 1 5  
 59 <210> SEQ ID NO: 3  
 60 <211> LENGTH: 4  
 61 <212> TYPE: PRT  
 62 <213> ORGANISM: Artificial Sequence  
 64 <220> FEATURE:  
 65 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve

therapeutic

66

effects in mammals.

## RAW SEQUENCE LISTING

DATE: 05/17/2002

PATENT APPLICATION: US/10/024,535A

TIME: 14:13:47

Input Set : A:\SEQ.10-024535.txt

Output Set: N:\CRF3\05172002\J024535A.raw

```

68 <220> FEATURE:
69 <221> NAME/KEY: MISC_FEATURE
70 <222> LOCATION: (1)..(1)
71 <223> OTHER INFORMATION: Xaa is Glp
74 <400> SEQUENCE: 3
W--> 75 Xaa His Asn Pro
76      1
78 <210> SEQ ID NO: 4
79 <211> LENGTH: 4
80 <212> TYPE: PRT
81 <213> ORGANISM: Artificial Sequence
83 <220> FEATURE:
84 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve
therapeutic
85      effects in mammals.
88 <400> SEQUENCE: 4
89 Gln His Asn Pro
90      1
92 <210> SEQ ID NO: 5
93 <211> LENGTH: 6
94 <212> TYPE: PRT
95 <213> ORGANISM: Artificial Sequence
97 <220> FEATURE:
98 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve
therapeutic
99      effects in mammals.
101 <400> SEQUENCE: 5
102 Arg Gln His Asn Pro Arg
103      1              5
105 <210> SEQ ID NO: 6
106 <211> LENGTH: 11
107 <212> TYPE: PRT
108 <213> ORGANISM: Artificial Sequence
110 <220> FEATURE:
111 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve
therapeutic
112      effects in mammals.
115 <400> SEQUENCE: 6
116 Val Arg Gly Pro Arg Arg Gln His Asn Pro Arg
117      1              5              10
119 <210> SEQ ID NO: 7
120 <211> LENGTH: 5
121 <212> TYPE: PRT
122 <213> ORGANISM: Artificial Sequence
124 <220> FEATURE:
125 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve
therapeutic
126      effects in mammals.
128 <400> SEQUENCE: 7
129 Gln His Asn Leu Arg
130      1              5
133 <210> SEQ ID NO: 8
134 <211> LENGTH: 6

```

## RAW SEQUENCE LISTING

DATE: 05/17/2002

PATENT APPLICATION: US/10/024,535A

TIME: 14:13:47

Input Set : A:\SEQ.10-024535.txt

Output Set: N:\CRF3\05172002\J024535A.raw

135 <212> TYPE: PRT  
136 <213> ORGANISM: Artificial Sequence  
138 <220> FEATURE:  
139 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve  
therapeutic  
140 effects in mammals.  
142 <400> SEQUENCE: 8  
143 Arg Gln His Asn Leu Arg  
144 1 5  
147 <210> SEQ ID NO: 9  
148 <211> LENGTH: 6  
149 <212> TYPE: PRT  
150 <213> ORGANISM: Artificial Sequence  
152 <220> FEATURE:  
153 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve  
therapeutic  
154 effects in mammals.  
156 <400> SEQUENCE: 9  
157 Gly Gln His Gly Pro Arg  
158 1 5  
160 <210> SEQ ID NO: 10  
161 <211> LENGTH: 6  
162 <212> TYPE: PRT  
163 <213> ORGANISM: Artificial Sequence  
165 <220> FEATURE:  
166 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve  
therapeutic  
167 effects in mammals.  
169 <400> SEQUENCE: 10  
170 Gly Gln His Asp Pro Thr  
171 1 5

RAW SEQUENCE LISTING ERROR SUMMARY      DATE: 05/17/2002  
PATENT APPLICATION: US/10/024,535A      TIME: 14:13:48

Input Set : A:\SEQ.10-024535.txt  
Output Set: N:\CRF3\05172002\J024535A.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 1

Seq#:3; Xaa Pos. 1

## VERIFICATION SUMMARY

DATE: 05/17/2002

PATENT APPLICATION: US/10/024,535A

TIME: 14:13:48

Input Set : A:\SEQ.10-024535.txt

Output Set: N:\CRF3\05172002\J024535A.raw

L:39 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0

L:75 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:0